Search

Your search keyword '"Miles, Rodney R."' showing total 171 results
Start Over Author "Miles, Rodney R." Language english
171 results on '"Miles, Rodney R."'

1. Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS: MYELODYSPLASTIC NEOPLASM

Author

Li, Peng, Alnoor, F. N. U., Xie, Wei, Williams, Margaret, Feusier, Julie, Ding, Yi, Zhao, Xiangrong, Zheng, Gang, Zhao, Chen, Zieske, Arthur W., Zu, Youli, Raess, Philipp W., Tantravahi, Srinivas, Osman, Afaf, Patel, Ami B., Tashi, Tsewang, Patel, Jay L., Matynia, Anna P., Menon, Madhu P., Miles, Rodney R., Jacobsen, Jeffrey R., George, Tracy I., Sborov, Douglas W., Szankasi, Philippe, Rindler, Paul, Close, Devin, and Ohgami, Robert S.

Published
2025
Full Text
View/download PDF

3. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma

Author

Goldman, Stan, Barth, Matthew, Shiramizu, Bruce, Shi, Qiuhu, Hochberg, Jessica, Klejmont, Liana, Harrison, Lauren, Basso, Jackie, Chu, Yaya, Islam, Humayun, Gerard, Perry, Agsalda-Garcia, Melissa, Shieh, Tiffany, Oesterheld, Javier, Heym, Kenneth, Kirov, Ivan, Drachtman, Richard, Harker-Murray, Paul, Perkins, Sherrie, Miles, Rodney R., and Cairo, Mitchell

Published
2021
Full Text
View/download PDF

4. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

Author

Viola, Domenico, Dona, Ada, Caserta, Enrico, Troadec, Estelle, Besi, Francesca, McDonald, Tinisha, Ghoda, Lucy, Gunes, Emine Gulsen, Sanchez, James F., Khalife, Jihane, Martella, Marianna, Karanes, Chatchada, Htut, Myo, Wang, Xiuli, Rosenzweig, Michael, Chowdhury, Arnab, Sborov, Douglas, Miles, Rodney R., Yazaki, Paul J., Ebner, Todd, Hofmeister, Craig C., Forman, Stephen J., Rosen, Steven T., Marcucci, Guido, Shively, John, Keats, Jonathan J., Krishnan, Amrita, and Pichiorri, Flavia

Published
2021
Full Text
View/download PDF

5. The whole-genome landscape of Burkitt lymphoma subtypes

Author

Panea, Razvan I., Love, Cassandra L., Shingleton, Jennifer R., Reddy, Anupama, Bailey, Jeffrey A., Moormann, Ann M., Otieno, Juliana A., Ong'echa, John Michael, Oduor, Cliff I., Schroeder, Kristin M.S., Masalu, Nestory, Chao, Nelson J., Agajanian, Megan, Major, Michael B., Fedoriw, Yuri, Richards, Kristy L., Rymkiewicz, Grzegorz, Miles, Rodney R., Alobeid, Bachir, Bhagat, Govind, Flowers, Christopher R., Ondrejka, Sarah L., Hsi, Eric D., Choi, William W.L., Au-Yeung, Rex K.H., Hartmann, Wolfgang, Lenz, Georg, Meyerson, Howard, Lin, Yen-Yu, Zhuang, Yuan, Luftig, Micah A., Waldrop, Alexander, Dave, Tushar, Thakkar, Devang, Sahay, Harshit, Li, Guojie, Palus, Brooke C., Seshadri, Vidya, Kim, So Young, Gascoyne, Randy D., Levy, Shawn, Mukhopadyay, Minerva, Dunson, David B., and Dave, Sandeep S.

Published
2019
Full Text
View/download PDF

7. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children

Author

Pearson, Andrew D.J., Scobie, Nicole, Norga, Koenraad, Ligas, Franca, Chiodin, Davy, Burke, Amos, Minard-Colin, Veronique, Adamson, Peter, Marshall, Lynley V., Balakumaran, Arun, Benettaib, Bouchra, Bhargava, Pankaj, Bollard, Catherine M., Bolotin, Ellen, Bomken, Simon, Buechner, Jochen, Burkhardt, Birgit, Caron, Hubert, Copland, Christopher, Demolis, Pierre, Egorov, Anton, Farhan, Mahdi, Zugmaier, Gerhard, Gross, Thomas, Horton-Taylor, Danielle, Klapper, Wolfram, Lesa, Giovanni, Marcus, Robert, Miles, Rodney R., Nottage, Kerri, Pacaud, Lida, Ricafort, Rosanna, Schrappe, Martin, Sterba, Jaroslav, Vezan, Remus, Weiner, Susan, Kim, Su Young, Reaman, Gregory, and Vassal, Gilles

Published
2019
Full Text
View/download PDF

9. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Author

Hayashi, Robert J., Hermiston, Michelle L., Wood, Brent L., Teachey, David T., Devidas, Meenakshi, Chen, Zhiguo, Annett, Robert D., Asselin, Barbara L., August, Keith, Cho, Steve, Dunsmore, Kimberly P., Freedman, Jason Lawrence, Galardy, Paul J., Harker-Murray, Paul, Horton, Terzah M., Jaju, Alok, Lam, Allison, Messinger, Yoav H., Miles, Rodney R., Okada, Maki, Patel, Samir, Schafer, Eric S., Schechter, Tal, Shimano, Kristin A., Singh, Neelam, Steele, Amii, Sulis, Maria L., Vargas, Sarah L., Winter, Stuart S., Wood, Charlotte, Zweidler-McKay, Patrick A., Loh, Mignon L., Hunger, Stephen P., Raetz, Elizabeth A., Bollard, Catherine M., and Allen, Carl E.

Published
2024
Full Text
View/download PDF

10. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets

Author

Bouska, Alyssa, Bi, Chengfeng, Lone, Waseem, Zhang, Weiwei, Kedwaii, Ambreen, Heavican, Tayla, Lachel, Cynthia M., Yu, Jiayu, Ferro, Roberto, Eldorghamy, Nanees, Greiner, Timothy C., Vose, Julie, Weisenburger, Dennis D., Gascoyne, Randy D., Rosenwald, Andreas, Ott, German, Campo, Elias, Rimsza, Lisa M., Jaffe, Elaine S., Braziel, Rita M., Siebert, Reiner, Miles, Rodney R., Dave, Sandeep, Reddy, Anupama, Delabie, Jan, Staudt, Louis M., Song, Joo Y., McKeithan, Timothy W., Fu, Kai, Green, Michael, Chan, Wing C., and Iqbal, Javeed

Published
2017
Full Text
View/download PDF

15. Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Author

Hayashi, Robert J., Hermiston, Michelle L., Teachey, David T., Devidas, Meenakshi, Wood, Brent L., Chen, Zhiguo, Annett, Robert D, Asselin, Barbara L, August, Keith J, Cho, Steve Y, Dunsmore, Kimberly P., Freedman, Jason L., Galardy, Paul J., Harker-Murray, Paul, Horton, Terzah M., Jaju, Alok I, Lam, Allison, Messinger, Yoav H., Miles, Rodney R., Okada, Maki, Patel, Samir I, Schafer, Eric S, Schechter-Finkelstein, Tal, Shimano, Kristin A., Singh, Neelam, Steele, Amii C., Sulis, Maria Luisa, Vargas, Sarah L, Winter, Stuart S., Wood, Charlotte, Zweidler-McKay, Patrick A, Loh, Mignon L., Hunger, Stephen P., Raetz, Elizabeth A., Bollard, Catherine M, and Allen, Carl

Published
2022
Full Text
View/download PDF

16. Zebrafish screen identifies novel compound with selective toxicity against leukemia

Author

Ridges, Suzanne, Heaton, Will L., Joshi, Deepa, Choi, Henry, Eiring, Anna, Batchelor, Lance, Choudhry, Priya, Manos, Elizabeth J., Sofla, Hossein, Sanati, Ali, Welborn, Seth, Agarwal, Archana, Spangrude, Gerald J., Miles, Rodney R., Cox, James E., Frazer, J. Kimble, Deininger, Michael, Balan, Kaveri, Sigman, Matthew, Müschen, Markus, Perova, Tatiana, Johnson, Radia, Montpellier, Bertrand, Guidos, Cynthia J., Jones, David A., and Trede, Nikolaus S.

Published
2012
Full Text
View/download PDF

17. Proteasome function is required for platelet production

Author

Shi, Dallas S., Smith, Matthew C.P., Campbel, Robert A., Zimmerman, Patrick W., Franks, Zechariah B., Kraemer, Bjorn F., Machlus, Kellie R., Ling, Jing, Kamba, Patrick, Schwertz, Hansjorg, Rowley, Jesse W., Miles, Rodney R., Liu, Zhi-Jian, Sola-Visner, Martha, Italiano, Jr., Joseph E., Christensen, Hilary, Kahr, Walter H.A., Li, Dean Y., and Weyrich, Andrew S.

Subjects
Ubiquitin-proteasome system -- Research, Bone marrow cells -- Physiological aspects, Bortezomib -- Complications and side effects, Thrombocytopenia -- Causes of, Health care industry
Abstract

The proteasome inhibiter bortezomib has been successfully used to treat patients with relapsed multiple myeloma; however, many of these patients become thrombocytopenic, and it is not clear how the proteasome influences platelet production. Here we determined that pharmacologic inhibition of proteasome activity blocks proplatelet formation in human and mouse megakaryocytes. We also found that megakaryocytes isolated from mice deficient for PSMC1, an essential subunit of the 26S proteasome, fail to produce proplatelets. Consistent with decreased proplatelet formation, mice lacking PSMC1 in platelets ([Psmc1.sup.fl/fl] Pf4-Cre mice) exhibited severe thrombocytopenia and died shortly after birth. The failure to produce proplatelets in proteasome-inhibited megakaryocytes was due to upregulation and hyperactivation of the small GTPase, RhoA, rather than NF-κB, as has been previously suggested. Inhibition of RhoA or its downstream target, Rho-associated protein kinase (ROCK), restored megakaryocyte proplatelet formation in the setting of proteasome inhibition in vitro. Similarly, fasudil, a ROCK inhibitor used clinically to treat cerebral vasospasm, restored platelet counts in adult mice that were made thrombocytopenic by tamoxifen-induced suppression of proteasome activity in megakaryocytes and platelets ([Psmc1.sup.fl/fl] PdgfCre-ER mice). These results indicate that proteasome function is critical for thrombopoiesis, and suggest inhibition of RhoA signaling as a potential strategy to treat thrombocytopenia in bortezomib-treated multiple myeloma patients., Introduction Thrombocytopenia (low platelet count) is observed in numerous diseases and can be life threatening due to bleeding complications. Bortezomib, a reversible chemotherapeutic inhibitor used to treat patients with relapsed [...]

Published
2014
Full Text
View/download PDF

21. Targeted Immunotherapy and Checkpoint Blockade in Children, Adolescents, and Young Adults with Lymphoma: Radical Hodgkin Cohort

Author

Klose, Kayleigh, Hochberg, Jessica, Basso, Jaclyn, Xavier, Ana C., Barth, Matthew J., Miles, Rodney R., Kahwash, Samir, Voss, Stephan D., Braniecki, Suzanne, Moorthy, Chitti, Armenian, Saro, Ehrhardt, Matthew J., Lim, Megan, Harrison, Lauren, Budhram, Arvind, Stonberg, Ariel, Goldman, Stanton, and Cairo, Mitchell S.

Published
2023
Full Text
View/download PDF

22. Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Author

Audino, Anthony N., Goldman, Stanton, Barth, Matthew J., Hochberg, Jessica, Xavier, Ana C., Shiramizu, Bruce, Shi, Qiuhu, Harrison, Lauren, Basso, Jackie, Oesterheld, Javier, Heym, Kenneth Matthew, Drachtman, Richard A., Harker-Murray, Paul, Perkins, Sherrie L., Miles, Rodney R., and Cairo, Mitchell S.

Published
2023
Full Text
View/download PDF

23. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children

Author

Minard-Colin, Véronique, Aupérin, Anne, Pillon, Marta, Burke, G A Amos, Barkauskas, Donald A, Wheatley, Keith, Delgado, Rafael F, Alexander, Sarah, Uyttebroeck, Anne, Bollard, Catherine M, Zsiros, József, Csoka, Monika, Kazanowska, Bernarda, Chiang, Alan K, Miles, Rodney R, Wotherspoon, Andrew, Adamson, Peter C, Vassal, Gilles, Patte, Catherine, Gross, Thomas G, European Intergroup for Childhood Non-Hodgkin Lymphoma, Children’s Oncology Group, Brichard, Bénédicte, Clinical sciences, Growth and Development, Pediatrics, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique

Subjects
Oncology, Male, Pediatrics, medicine.medical_treatment, Lymphoma, B-Cell/drug therapy, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Rituximab/administration & dosage, Antineoplastic Agents, Immunological, 0302 clinical medicine, Neutropenia/chemically induced, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Child, Infusions, Intravenous, Medicine(all), General Medicine, Progression-Free Survival, Mature B-Cell Non-Hodgkin's Lymphoma, Rituximab, Female, Lymph, medicine.drug, medicine.medical_specialty, Lymphoma, B-Cell, Neutropenia, Adolescent, Child, preschool, Infections/etiology, MEDLINE, Infections, Article, 03 medical and health sciences, Antineoplastic Agents, Immunological/administration & dosage, Internal medicine, medicine, Humans, Progression-free survival, Chemotherapy, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cancer, medicine.disease, Lymphoma, Clinical trial, business, Follow-Up Studies
Abstract

BACKGROUND: Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. METHODS: We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed. RESULTS: Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitt's lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximab-chemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [CI], 89.1 to 96.7) in the rituximab-chemotherapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-sided P = 0.00096, which reached the significance level required for this analysis). Eight patients in the rituximab-chemotherapy group died (4 deaths were disease-related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatment-related) (hazard ratio, 0.36; 95% CI, 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximab-chemotherapy group and 24.2% in the chemotherapy group (P = 0.07); events were related mainly to febrile neutropenia and infection. Approximately twice as many patients in the rituximab-chemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion. CONCLUSIONS: Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin's lymphoma and was associated with a higher incidence of hypogammaglobulinemia and, potentially, more episodes of infection. (Funded by the Clinical Research Hospital Program of the French Ministry of Health and others; ClinicalTrials.gov number, NCT01516580.).

Published
2020
Full Text
View/download PDF

33. Pediatric Diffuse Large B-Cell Lymphoma Demonstrates a High Proliferation Index, Frequent c-Myc Protein Expression, and a High Incidence of Germinal Center Subtype: Report of the French–American–British (FAB) International Study Group

Author

Miles, Rodney R., Raphael, Martine, McCarthy, Keith, Wotherspoon, Andrew, Lones, Mark A., Terrier-Lacombe, Marie J., Patte, Catherine, Gerrard, Mary, Auperin, Anne, Sposto, Richard, Davenport, Virginia, Cairo, Mitchell S., and Perkins, Sherrie L.

Published
2008
Full Text
View/download PDF

36. A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Author

Guest, Erin, Kairalla, John, Devidas, Meenakshi, Hibbitts, Emily, Carroll, Andrew J., Heerema, Nyla A., Kubaney, Holly, August, Amanda, Pauly, Melinda, Wechsler, Daniel, Miles, Rodney R., Reid, Joel M., Kihei, Cynthia, Gore, Lia, Raetz, Elizabeth A., Hunger, Stephen P., Loh, Mignon L., and Brown, Patrick A.

Published
2022
Full Text
View/download PDF

37. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.

Author

Burke, G A Amos, Minard-Colin, Veronique, Aupérin, Anne, Alexander, Sarah, Pillon, Marta, Delgado, Rafael, Zsíros, József, Uyttebroeck, Anne, Dartigues, Peggy, Miles, Rodney R, Kazanowska, Bernarda, Chiang, Alan K, Haouy, Stéphanie, Bollard, Catherine M, Csoka, Monika, Wheatley, Keith, Barkauskas, Donald A, Adamson, Peter C, Vassal, Gilles, and Patte, Catherine

Published
2021
Full Text
View/download PDF

39. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.

Author

Hayashi, Robert J., Winter, Stuart S., Dunsmore, Kimberly P., Devidas, Meenakshi, Chen, Zhiguo, Wood, Brent L., Hermiston, Michelle L., Teachey, David T., Perkins, Sherrie L., Miles, Rodney R., Raetz, Elizabeth A., Loh, Mignon L., Winick, Naomi J., Carroll, William L., Hunger, Stephen P., Lim, Megan S., Gross, Thomas G., and Bollard, Catherine M.

Published
2020
Full Text
View/download PDF

40. Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Author

Hochberg, Jessica C., Goldman, Stanton, Barth, Matthew J., Shi, Qiuhu, Klejmont, Liana, Harrison, Lauren, Basso, Jackie, Chu, Yaya, Islam, Humayun, Gerard, Perry, Oesterheld, Javier, Heym, Kenneth Matthew, Kirov, Ivan I., Drachtman, Richard A., Harker-Murray, Paul, Perkins, Sherrie L., Miles, Rodney R., Shiramizu, Bruce, and Cairo, Mitchell S

Published
2020
Full Text
View/download PDF

41. Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231

Author

Teachey, David T., Devidas, Meenakshi, Wood, Brent L, Chen, Zhiguo, Hayashi, Robert James, Annett, Robert D, Asselin, Barbara L, August, Keith J, Cho, Steve Y, Dunsmore, Kimberly P., Fisher, Brian T., Freedman, Jason L., Galardy, Paul J., Harker-Murray, Paul, Hermiston, Michelle L., Horton, Terzah M, Jaju, Alok I, Lam, Allison, Messinger, Yoav H., Miles, Rodney R., Okada, Maki, Patel, Samir I, Schafer, Eric S., Schechter-Finkelstein, Tal, Shimano, Kristin A., Singh, Neelam, Steele, Amii C., Sulis, Maria L., Vargas, Sarah L, Winter, Stuart S., Wood, Charlotte, McKay, Patrick Zweider, Bollard, Catherine M., Loh, Mignon L., Hunger, Stephen P., and Raetz, Elizabeth A.

Published
2020
Full Text
View/download PDF

43. Cutaneous T-Cell Acute Lymphoblastic Leukemia and the Expression Pattern of Terminal Deoxynucleotidyl Transferase Immunostaining in Mycosis Fungoides and Spongiotic Dermatitis.

Author

Clark, Joshua J., Hawkes, Jason E., Florell, Scott R., Miles, Rodney R., and Wada, David A.

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, IMMUNOSTAINING, MYCOSIS fungoides, SKIN inflammation, SKIN biopsy
Abstract

Background/Aims: T-cell acute lymphoblastic leukemia (T-ALL) is an uncommon, aggressive malignancy that rarely presents in the skin and is generally not considered as part of the differential diagnosis by dermatologists and dermatopathologists. We describe an unusual case of T-ALL presenting with folliculocentric, erythematous papules on the face, histologically resembling mycosis fungoides (MF). Immunostaining for terminal deoxynucleotidyl transferase (TdT) was positive in tumor cells, supporting the diagnosis of cutaneous involvement by T-ALL. TdT is a nuclear enzyme expressed by immature lymphoid malignancies, but the expression pattern of this marker is not well characterized in the skin. We aimed to assess TdT staining in skin biopsies with similar-appearing lymphocytic infiltrates. Methods: We evaluated the immunostaining profile of TdT in a cohort of 23 patients, including 13 cases of MF and 10 cases of spongiotic dermatitis. Results: The lymphocytes in the MF and spongiotic dermatitis cases lacked nuclear staining for TdT. Nonspecific, granular, cytoplasmic staining was observed in a small number of background cells. Conclusions: TdT may assist dermatopathologists in discriminating malignant infiltrates of T-ALL from other conditions. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. Lymphoma diagnostics: getting more from less.

Author

Galardy, Paul J., Bedekovics, Tibor, Macintyre, Elizabeth, and Miles, Rodney R.

Subjects
CORE needle biopsy, LYMPHOMAS, NEEDLE biopsy, GENETICS, BIOLOGY
Abstract

Summary: In the modern era, clinicians and pathologists increasingly make challenging diagnoses in patients with suspected lymphoma using minimal amounts of diagnostic material. The increase in utilization of minimally invasive procedures, such as fine needle aspiration or needle core biopsies, lead to challenges in our ability to make accurate histopathological assessments of disease, including the integration of new diagnostic and prognostic testing, with smaller amounts of material. The trend towards minimally invasive diagnostics is also often in conflicting interest with researchers seeking to study tissue specimens to better understand the biology and genetics of these diseases to move the field forward. Thankfully, there are emerging fields which seek to extract large amounts of diagnostic and prognostic data out of material that is circulating in the blood of patients with lymphoma. Here we will review recent exciting data regarding the use of circulating tumour cells, circulating tumour DNA, and the detection and utility of circulating exosomes and how it can assist in diagnosis, prognosis and therapeutic monitoring. These advances hold the promise to enable continued safe patient care while also advancing discovery, translational and clinical research. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

46. Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL)

Author

Hayashi, Robert James, Winter, Stuart S., Dunsmore, Kimberly P., Devidas, Meenakshi, Wood, Brent, Hermiston, Michelle L., Teachey, David T, Perkins, Sherrie L., Miles, Rodney R., Raetz, Elizabeth A., Loh, Mignon L., Winick, Naomi, Carroll, William L., Hunger, Stephen P., Lim, Megan S., Bollard, Catherine M., and Gross, Thomas G.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results